A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast

Plast Reconstr Surg. 2011 Sep;128(3):112e-118e. doi: 10.1097/PRS.0b013e318221db96.

Abstract

Implant-related primary anaplastic large cell lymphoma (ALCL) of the breast is a rare clinical entity. With increasing attention being paid to this disease, most cases reported to date in the literature have demonstrated indolent clinical courses responsive to explantation, capsulectomy, chemotherapy, and/or radiotherapy. The authors describe a case of bilateral implant-related primary ALCL of the breast that proved refractory to both standard and aggressive interventions, ultimately resulting in patient death secondary to disease progression. The authors situate this case in the context of the current state of knowledge regarding implant-related primary ALCL of the breast and suggest that this entity is generally, but not universally, indolent in nature.

Clinical question/level of evidence: Risk, V.

Publication types

  • Case Reports

MeSH terms

  • Breast / pathology
  • Breast Implants / adverse effects*
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy
  • Cause of Death
  • Combined Modality Therapy
  • Disease Progression
  • Female
  • Humans
  • Lymphoma, Large-Cell, Anaplastic / mortality*
  • Lymphoma, Large-Cell, Anaplastic / pathology
  • Lymphoma, Large-Cell, Anaplastic / therapy
  • Mastectomy
  • Middle Aged
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy
  • Neoplasm Staging
  • Neoplasms, Multiple Primary / mortality*
  • Neoplasms, Multiple Primary / pathology
  • Neoplasms, Multiple Primary / therapy
  • Postoperative Complications / mortality*
  • Postoperative Complications / pathology
  • Postoperative Complications / surgery
  • Prosthesis Failure
  • Reoperation
  • Silicone Gels

Substances

  • Silicone Gels